Company Overview and News

1
LYTS / LSI Industries, Inc. LSI INDUSTRIES INC. FORM SD MAY 31, 2018

2018-05-31 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
LYTS

95
45 Top Technology Dividend WallStars By Yield And Gains In May

2018-05-30 seekingalpha
Top WallStar Technology ten by broker estimated net gains, GLW, HIMX, AVGO, CAMT, PCTI, RELL, XRX, LYTS, TIVO, and XPER, averaged 41.15%, calculated 5/25/18.
GLW XPER RELLB XRX CAMT LYTS HIMX AVGO NOK RELL QCOM TESS TIVO

2
LYTS / LSI Industries, Inc. FORM 10-Q (Quarterly Report)

2018-05-08 sec.gov
lyts20180331_10q.htm UNITED STATES
LYTS

1
LYTS / LSI Industries, Inc. LSI INDUSTRIES INC. FORM 8-K APRIL 23, 2018 (Current Report)

2018-04-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 LYTS

24
Bear of the Day: Acuity Brands (AYI)

2018-04-27 zacks
Acuity Brands, Inc. (AYI - Free Report) missed for the second quarter in a row as the lighting market remains weak. This Zacks Rank #5 (Strong Sell) is expected to grow earnings by just 1.9% in Fiscal 2018. Acuity Brands is one of the leading providers of lighting and building management solutions in North America. It has operations throughout North America, Europe and Asia. It's products are sold under various brands including Lithonia Lighting, Holophane, Peerless, Gotham, Mark Architectural Lighting, Juno, Indy, Aculux, Antique Street Lamps, nLight, ROAM, Atrius and Lucid, among others.
QADA LYTS SQ SQNXF TUP QADB

8
LSI Industries' (LYTS) CEO John Morgan on Q3 2018 Results - Earnings Call Transcript

2018-04-27 seekingalpha
Good day, ladies and gentlemen, and welcome to the LSI Industries’ Third Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
LYTS XOM

1
BRIEF-Lsi Industries Announces Quarterly Reported EPS Of $0.01

2018-04-26 reuters
* LSI INDUSTRIES INC - NET SALES IN Q3 OF FISCAL 2018 WERE $78.8 MILLION, AN INCREASE OF 1% COMPARED TO Q3 OF PRIOR YEAR
LYTS

1
LYTS / LSI Industries, Inc. LSI INDUSTRIES INC. FORM 8-K APRIL 26, 2018 (Current Report)

2018-04-26 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 LYTS

1
LSI Industries Inc. Reports Operating Results for the Third Quarter and Nine Month Period Ended March 31, 2018; Declares Regular Cash Dividend; and Provides Update on CEO Search

2018-04-26 globenewswire
Net sales in the third quarter of fiscal 2018 were $78,843,000, an increase of 1% compared to the $78,156,000 reported in the third quarter of the prior year. Reported net income was $220,000 in the third quarter versus a loss of $(531,000) in Q3 FY 2017. Reported EPS of $0.01 is above reported EPS of $(0.02) for the third quarter of the prior year. Adjusted net income was $226,000 compared to $357,000 for third quarter FY 2017.
LYTS

1
LSI Industries Third Quarter, Fiscal 2018 Earnings Conference Call Update

2018-04-24 globenewswire
CINCINNATI, April 24, 2018 (GLOBE NEWSWIRE) -- LSI Industries Inc. (NASDAQ:LYTS) today provided an update on the third quarter, fiscal 2018 earnings conference call. John Morgan, Managing Director, commented, “The Company has received a number of inquiries from shareholders with regard to the recent departure of the CEO and the effect this may have on the conference call scheduled for Thursday April 26th.
LYTS

15
LSI Industries Inc. Names Ronald D. Brown Interim CEO and Crawford Lipsey as Interim COO

2018-04-23 globenewswire
CINCINNATI, April 23, 2018 (GLOBE NEWSWIRE) -- LSI Industries Inc. (NASDAQ:LYTS) today announced that its board of directors appointed Ronald D. Brown as interim chief executive officer and Crawford Lipsey as interim president and chief operating officer effective immediately. The hiring of Brown and Lipsey follows the departure of Dennis W. Wells as president and chief executive officer on April 23, 2018.
LYTS AOS

1
LSI Industries Inc. Schedules Conference Call to Discuss Third Quarter Fiscal 2018 Results

2018-04-20 globenewswire
CINCINNATI, Ohio, April 20, 2018 (GLOBE NEWSWIRE) -- LSI Industries Inc. (NASDAQ:LYTS) today announced that the Company will host a conference call to discuss third quarter fiscal 2018 results on April 26, 2018 at 10:00 a.m. EDT. The earnings announcement will be issued prior to market open that same day.
LYTS

167
10 Stocks to Short as China Hits Back

2018-04-13 investorplace
U.S. equity markets have been much choppier so far in 2018, to say the least. Volatility has doubled. February saw the first market correction in two years. And since then, U.S. stocks have swung back and forth, with a number of big one-day moves along the way.
LZB MGM ROLL TIF CAT CPB CLD LYTS ACI BOE BTUUQ ARCH HOFT POL ELY CATR WYNN SJM CLDEP HOG W ACIIQ BTU BTU.PR BSET LVS BA DE

45
Depressed LED Players Set For A Rebound

2018-03-20 seekingalpha
The current downturn in the LED lighting market appears to be nearing a turning point, boosted by tax reform, repatriation, and improving business sentiment.
OESX AYI FLEX OSAGY GE EFOI CREE NXPI ETN FSL RVLT LYTS PHPPY

17
Director's Letter Micro Cap Summary - March 2018

2018-03-15 seekingalpha
After a near two year hiatus, with the VIX trending at the historical low end of 11-14 bp level, volatility exploded in early February after an employment report showed higher than expected wage growth, pointing to higher interest rates. All the leveraged short vol funds took a huge hit that sent shock waves into the broader equity market, creating the first 10% sell off since early 2016. Better than expected earnings, upward revisions and positive economic news led the markets to rebound for only a 3-4% down month for February.
AMRK HNNA LYTS ANIK FLL HBP NYTAB NYT NMIH

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to LYTS / LSI Industries, Inc. on message board site Silicon Investor.

LYTS - LSI Inds Inc
CUSIP: 50216C108